ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1250

Qualitative Study on Patient-Reported Outcome Measures in Patients with Sjögren’s Disease

Suzanne Arends1, Jiyoon C. Choi2, Brandon Becker2, Teresa Edwards3, Antoine Sreih4, Antonia Christodoulou4 and Vibeke Strand5, 1Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2Bristol Myers Squibb, Princeton, 3RTI International, Research Triangle Park, NC, 4Bristol Myers Squibb, Princeton, NJ, 5Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA

Meeting: ACR Convergence 2024

Keywords: Patient reported outcomes, Qualitative Research, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Patient Outcomes, Preferences, & Attitudes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by lymphocytic infiltration of the endocrine glands. Globally, SjD affects between 0.01% and 0.05% of the population, yet it may affect as many as 4 million people in the US. Ocular and oral dryness, muscle/joint pain, and fatigue are commonly reported symptoms in SjD. In this qualitative study, participants with SjD were interviewed to understand the nature and relative importance of SjD symptoms, to evaluate the content validity of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) in the context of SjD, and to assess the understandability of the symptom-specific Numeric Rating Scales (NRSs).

Methods: In June 2023, in-depth individual interviews were conducted with 15 adults in the US with self-reported clinician-diagnosed SjD not associated with other autoimmune rheumatic diseases. Participants were required to have self-reported moderate to severe oral dryness, ocular dryness, and/or muscle/joint pain in the 30 days prior to interview. Each 60-minute virtual interview was conducted in English in a hybrid (concept elicitation/cognitive debriefing) semistructured format, using an interview guide to encourage response spontaneity and to ensure consistent, systematic data collection. SjD symptoms experienced by participants were reported via concept elicitation. Participant feedback was generated using the 13-item FACIT-Fatigue scale for symptoms of fatigue and the symptom-specific NRS items for daily symptoms of ocular and oral dryness and muscle/joint pain. Regarding the ACR classification criteria for SjD, all diagnoses were self-reported as being physician diagnosed.

Results: The 15 participants interviewed had a mean age of 50.6 years (range: 30–71); 86.7% (n=13) were female and 80.0% (n=12) were White (Table). The mean time since clinical diagnosis of SjD was 6 years (range: 3–10). More than 85% of participants reported experiencing ocular and oral dryness, fatigue, and muscle/joint pain due to SjD; these symptoms were also reported as the most bothersome (53% ocular dryness; 40% oral dryness; 27% muscle/joint pain; 13% fatigue). Most participants (86.7%; n=13) reported that the FACIT-Fatigue scale captured all important aspects of SjD-associated fatigue. The remaining participants (n=2) identified 2 items as potentially not relevant to their own experience of fatigue. Additionally, 93.3% of participants (n=14) reported easy recall of fatigue symptoms during the previous 7 days. Debriefing results also showed that participants were able to easily understand and provide a response to symptom-specific NRS items, with no difficulties reported regarding the 24-hour recall period.

Conclusion: Interview results support the content validity of the FACIT-Fatigue scale and the relevance of symptom-specific NRS items in patients with SjD. The results also show that the FACIT-Fatigue scale and the NRS items were well understood, easily completed, and captured relevant symptoms experienced by a majority of patients with SjD, which supports the use of these patient-reported outcomes in phase 3 trials.

Supporting image 1


Disclosures: S. Arends: Argenx, 2, Bristol Myers Squibb, 2, Galápagos, 2, Novartis, 2; J. Choi: Bristol Myers Squibb, 3, 12, Shareholder, Johnson & Johnson, 12, Shareholder; B. Becker: Bristol Myers Squibb, 3, 12, Shareholder; T. Edwards: None; A. Sreih: Bristol Myers Squibb, 3, 12, Shareholder; A. Christodoulou: Bristol Myers Squibb, 3, 12, Shareholder; V. Strand: AbbVie, 1, 2, Alpine Immune Sciences, 1, 2, Alumis, 1, 2, Amgen, 1, 2, AstraZeneca, 1, 2, Bayer, 1, 2, Blackrock Pharmaceuticals, 1, 2, Boehringer Ingelheim, 1, 2, Bristol Myers Squibb, 1, 2, Celltrion, 1, 2, Citryll, 1, 2, Contura, 1, 2, Equillium, 1, 2, Fortress Biotech, 1, 2, Genentech/Roche, 1, 2, GSK, 1, 2, Inmedix, 1, 2, Janssen, 1, 2, Kiniksa, 1, 2, Lilly, 1, 2, Novartis, 1, 2, Omeros, 1, 2, Pfizer, 1, 2, Priovant Therapeutics, 1, 2, Rapt Therapeutics, 1, 2, Regeneron, 1, 2, R-Pharm, 1, 2, Samsung, 1, 2, Sandoz, 1, 2, Sanofi, 1, 2, Scipher, 1, 2, SetPoint Medical, 1, 2, Sobi, 1, 2, Spherix, 1, 2, SynAct Pharma, 1, 2, Takeda Pharmaceuticals, 1, 2.

To cite this abstract in AMA style:

Arends S, Choi J, Becker B, Edwards T, Sreih A, Christodoulou A, Strand V. Qualitative Study on Patient-Reported Outcome Measures in Patients with Sjögren’s Disease [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/qualitative-study-on-patient-reported-outcome-measures-in-patients-with-sjogrens-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/qualitative-study-on-patient-reported-outcome-measures-in-patients-with-sjogrens-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology